Nyxoah to Present at the J.P. Morgan Healthcare Conference in January

Presentation Details

According to the company, Nyxoah's management will speak at the conference on Thursday, January 15, 2026, at 12 PM Pacific Time. The presentation will be available online through a live audio webcast on the company's Investor Relations page, the statement indicates. Based in Mont-Saint-Guibert, Belgium, Nyxoah is listed on both Euronext Brussels and the Nasdaq following its respective IPOs in September 2020 and July 2021.

Focus on Sleep Apnea Solutions

Nyxoah is dedicated to the development and marketing of innovative solutions for treating obstructive sleep apnea syndrome, the group specifies. Its flagship solution, the Genio system, is a probeless and batteryless hypoglossal nerve neurostimulation therapy, which received European CE marking in 2019 following the BLAST OSA study. The device aims to treat this sleep-related breathing disorder, which the company associates with an increased risk of mortality and various cardiovascular comorbidities.

Regulatory Advancements

The group notes that the Genio system received CE marking for an extension of its therapeutic indications to patients suffering from complete concentric collapse, for whom competing therapies are currently contraindicated, thanks to the positive results of the BETTER SLEEP study. Furthermore, Nyxoah announced that it has received FDA approval for a subgroup of adult patients with moderate to severe obstructive sleep apnea, with an apnea-hypopnea index of 15 to 65, following the positive outcomes of the pivotal DREAM IDE study.